Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models

European Journal of Pharmacology

Volumn 606, Issue 1-3, 2009, Pages 102-108

  Yoshikawa, Satoru ^a,b   Hareyama, Nana ^a   Ikeda, Ken ^a   Kurokawa, Takahiro ^a   Nakajima, Mayumi ^a   Nakao, Kaoru ^a   Mochizuki, Hidenori ^a   Ichinose, Hiroshi ^b  

^a TORAY INDUSTRIES INC   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Biochemical change; Kappa opioid receptor; Locomotion; Schizophrenia; Stereotyped behavior; TRK 820

Indexed keywords

DOPAMINE; HALOPERIDOL; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; NALFURAFINE; NORBINALTORPHIMINE; PHENCYCLIDINE; RISPERIDONE; SEROTONIN;

ABNORMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG MECHANISM; LOCOMOTION; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; EXTRACELLULAR SPACE; HYPERKINESIS; MALE; MORPHINANS; NALTREXONE; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SCHIZOPHRENIA; SEROTONIN; SPIRO COMPOUNDS;

EID: 60949099290     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.01.043     Document Type: Article

References (58)

1. Adams B., and Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 18 (1998) 5545-5554
2. Arvidsson U., Riedl M., Chakrabarti S., Vulchanova L., Lee J.H., Nakano A.H., Lin X., Loh H.H., Law P.Y., Wessendorf M.W., and Elde R. The kappa-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 5062-5066
3. Berger B., Rothmaier A.K., Wedekind F., Zentner J., Feuerstein T.J., and Jackisch R. Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex. Br. J. Pharmacol. 148 (2006) 795-806
4. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am. J. Psychiatry 135 (1978) 165-173
5. Chrtoff E.H., Heusner C.L.H., and Palmiter R.D. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonist. Neuropsychopharmacology 30 (2005) 1324-1333
6. Di Pietro N.C., and Seamans J.K. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry 40 (2007) S27-S33
7. Dykstra L.A., Gmerek D.E., Winger G., and Woods J.H. Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J. Pharmacol. Exp. Ther. 242 (1987) 413-420
8. Endoh T., Matsuura H., Tajima A., Izumimoto N., Tajima C., Suzuki T., Saitoh A., Suzuki T., Narita M., Tseng L., and Nagase H. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist. Life Sci. 65 (1999) 1685-1694
9. Endoh T., Matsuura H., Tanaka C., and Nagase H. Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int. Pharmacodyn. Ther. 316 (1992) 30-42
10. Etou K., Kuroki T., Kawahara T., Yonezawa Y., Tashiro N., and Uchimura H. Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex. Pharmacol. Biochem. Behav. 61 (1998) 427-434
11. Feenstra M.G., Botterblom M.H., and van Uum J.F. Behavioral arousal and increased dopamine efflux after blockade of NMDA-receptors in the prefrontal cortex are dependent on activation of glutamatergic neurotransmission. Neuropharmacology 42 (2002) 752-763
12. Gene G., Kinney, Cyrille, and Sur. Glycine site modulators and glycine transporter-1 inhibitors as novel therapeutic targets for the treatment of schizophrenia. Curr. Neuropharmacol. 3 (2005) 35-43
13. Geyer M.A., and Moghaddam B. Animal models relevant to schizophrenia disorder. In: Davis K.L., Chrarney C., Coyle J.T., and Nemeroff C. (Eds). Psychopharmacology: The Fifth Generation of Progress (2002), Philadelphia, Lippinocott Williams and Wilkins
14. Gleason S.D., and Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 129 (1997) 79-84
15. Hasebe K., Kawai K., Suzuki T., Kawamura K., Tanaka T., Narita M., Nagase H., and Suzuki T. Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. Ann. N. Y. Acad. Sci. 1025 (2004) 404-413
16. Hervé D., Pickel V.M., Joh T.H., and Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res. 435 (1987) 71-83
17. Homayoun H., and Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 24 (2007) 11496-11500
18. Hondo H., Yonezawa Y., Nakahara T., Nakamura K., Hirano M., Uchimura H., and Tashiro N. Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res. 633 (1994) 337-342
19. Jentsch J.D., Tran A., Taylor J.R., and Roth R.H. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology (Berl.) 138 (1998) 89-95
20. Kitaichi K., Yamada K., Hasegawa T., Furukawa H., and Nabeshima T. Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin. Jpn. J. Pharmacol. 66 (1994) 181-189
21. Krebs-Thomson K., Lehmann-Masten V., Naiem S., Paulus M.P., and Geyer M.A. Modulation of phencyclidine-induced changes in locomotor activity and patterns in rats by serotonin. Eur. J. Pharmacol. 343 (1998) 135-143
22. Kumagai H., Saruta T., Matsukawa S., and Utsumi J. Prospects for a novel κ-opioid receptor agonist, TRK-820, in uremic pruritus. In: Yosipovitch G., Greaves M.W., Fleischer Jr. A.B., and McGlone F. (Eds). Itch/Basic Mechanisms and Therapy (2004), Marcel Dekker, New York, NY 279-286
23. Mansour A., Burke S., Pavlic R.J., Akil H., and Watson S.J. Immunohistochemical localization of the cloned kappa 1 receptor in the rat CNS and pituitary. Neuroscience 71 (1996) 671-690
24. Margolis E.B. Both kappa and mu opioid agonists inhibit glutamatergic input to ventral tegmental area neurons. J. Neurophysiol. 93 (2005) 3086-3093
25. Margolis E.B., Lock H., Chefer V.I., Shippenberg T.S., Hjelmstad G.O., and Fields H.L. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 2938-2942
26. Megens A.A., Niemegeers C.J., and Awouters F.H. Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol. J. Pharmacol. Exp. Ther. 260 (1992) 160-167
27. 2A sites for PCP-induced locomotion in the rat. Eur. J. Neurosci. 11 (1999) 4419-4432
28. Moore H., West A.R., and Grace A.A. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol. Psychiatry 46 (1999) 40-55
29. Mori T., Nomura M., Yoshizawa K., Nagase H., Narita M., and Suzuki T. Differential properties between TRK-820 and U-50,488H on the discriminative stimulus effects in rats. Life Sci. 75 (2004) 2473-2482
30. Mori T., Nomura M., Yoshizawa K., Nagase H., Sawaguchi T., Narita M., and Suzuki T. Generalization of NMDA-receptor antagonists to the discriminative stimulus effects of kappa-opioid receptor agonists U-50,488H, but not TRK-820 in rats. J. Pharmacol. Sci. 100 (2006) 157-161
31. Nabeshima T., Noda Y., Yamaguchi K., Ishikawa K., Furukawa H., and Kameyama T. Acute and chronic phencyclidine administration changes serotonin receptors in rat brain. Eur. J. Pharmacol. 109 (1985) 129-130
32. Nabeshima T., Yamaguchi K., Hiramatsu M., Amano M., Furukawa H., and Kameyama T. Serotonergic involvement in phencyclidine-induced behaviors. Pharmacol. Biochem. Behav. 21 (1984) 401-408
33. Nabeshima T., Yamaguchi K., Ishikawa K., Furukawa H., and Kameyama T. Potentiation in phencyclidine-induced serotonin-mediated behaviors after intracerebroventricular administration of 5,7-dihydroxytryptamine in rats. J. Pharmacol. Exp. Ther. 243 (1987) 1139-1146
34. Nagase H., Hayakawa J., Kawamura K., Kawai K., Takezawa Y., Matsuura H., Tajima C., and Endo T. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan. Chem. Pharm. Bull. (Tokyo), 46 (1998) 366-369
35. Nakao K., Ikeda K., Kurokawa T., Togashi Y., Umeuchi H., Honda T., Okano K., and Mochizuki H. Effect of TRK-820, a selective κ opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis. Jpn. J. Neuropsychopharmacol. 28 (2008) 75-83
36. Noda Y., Kamei H., Mamiya T., Furukawa H., and Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 23 (2000) 375-387
37. Olszewski R.T., Bukhari N., Zhou J., Kozikowski A.P., Wroblewski J.T., Shamimi-Noori S., Wroblewska B., Bzdega T., Vicini S., Barton F.B., and Neale J.H. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J. Neurochem. 89 (2004) 876-885
38. O'Neill K.A., and Liebman J.M. Unique behavioral effects of the NMDA antagonist, CPP, upon injection into the medial pre-frontal cortex of rats. Brain Res. 435 (1987) 371-376
39. Pfeiffer A., Brantl V., Herz A., and Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science 233 (1986) 774-776
40. Rimoy G.H., Wright D.M., Bhaskar N.K., and Rubin P.C. The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist. Eur. J. Clin. Pharmacol., 46 (1994) 203-207
41. Schiffer W.K., Gerasimov M., Hofmann L., Marsteller D., Ashby C.R., Brodie J.D., Alexoff D.L., and Dewey S.L. Gamma vinyl-GABA differentially modulates NMDA antagonist-induced increases in mesocortical versus mesolimbic DA transmission. Neuropsychopharmacology 25 (2001) 704-712
42. 2A/2C receptors. Eur. J. Pharmacol. 564 (2007) 123-130
43. Suzuki T., Izumimoto N., Takezawa Y., Fujimura M., Togashi Y., Nagase H., Tanaka T., and Endoh T. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions. Brain Res. 995 (2004) 167-175
44. Takahashi S., Horikomi K., and Kato T. MS-377, a novel selective sigma(1) receptor ligand, reverses phencyclidine-induced release of dopamine and serotonin in rat brain. Eur. J. Pharmacol. 427 (2001) 211-219
45. Takahashi S., Sonehara K., Takagi K., Miwa T., Horikomi K., Mita N., Nagase H., Iizuka K., and Sakai K. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors. Psychopharmacology (Berl.) 145 (1999) 295-302
46. Takahata R., and Moghaddam B. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 28 (2003) 1117-1124
47. Takemori A.E., Ho B.Y., Naeseth J.S., and Portoghese P.S. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 246 (1988) 255-258
48. Tao R., and Auerbach S.B. mu-Opioids disinhibit and kappa-opioids inhibit serotonin efflux in the dorsal raphe nucleus. Brain Res. 1049 (2005) 70-79
49. Thierry A.M., Blanc G., Sobel A., Stinus L., and Golwinski J. Dopaminergic terminals in the rat cortex. Science 182 (1973) 499-501
50. Togashi Y., Umeuchi H., Okano K., Ando N., Yoshizawa Y., Honda T., Kawamura K., Endoh T., Utsumi J., Kamei J., Tanaka T., and Nagase H. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur. J. Pharmacol. 435 (2002) 259-264
51. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42 (2001) 165-179
52. Tsuji M., Takeda H., Matsumiya T., Nagase H., Narita M., and Suzuki T. The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. Life Sci. 68 (2001) 1717-1725
53. Tsuji M., Takeda H., Matsumiya T., Nagase H., Yamazaki M., Narita M., and Suzuki T. A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice. Life Sci. 66 (2000) 353-358
54. Umeuchi H., Togashi Y., Honda T., Nakao K., Okano K., Tanaka T., and Nagase H. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur. J. Pharmacol. 477 (2003) 29-35
55. Wikström B., Gellert R., Ladefoged S.D., Danda Y., Akai M., Ide K., Ogasawara M., Kawashima Y., Ueno K., Mori A., and Ueno Y. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J. Am. Soc. Nephrol. 16 (2005) 3742-3747
56. Williams S.M., and Goldman-Rakic P.S. Characterization of the dopaminergic innervation of the primate frontal cortex using a dopamine-specific antibody. Cereb. Cortex. 3 (1993) 199-222
57. Yamaguchi K., Nabeshima T., and Kameyama T. Potentiation of phencyclidine-induced dopamine-dependent behaviors in rats after pretreatments with serotonin-depletors. J. Pharmacobiodyn. 9 (1986) 479-489
58. Yamaguchi K., Nabeshima T., and Kameyama T. Role of dopaminergic and serotonergic neuronal systems in the prefrontal cortex of rats in phencyclidine-induced behaviors. J. Pharmacobiodyn. 9 (1986) 987-996